Research progress in pharmacological and non-pharmacological treatments of hypertension
10.12092/j.issn.1009-2501.2022.04.013
- Author:
Jianfei XU
1
;
Li LIN
2
Author Information
1. Tongji University School of Medicine
2. Department of Cardiovascular Medicine, Dongfang Hospital Affiliated to Tongji University
- Publication Type:Journal Article
- Keywords:
Enkephalinase inhibitor;
GLP-1;
Hypertension;
Pharmacological treatment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):433-441
- CountryChina
- Language:Chinese
-
Abstract:
Hypertension is the most common chronic non-communicable disease in the world and the most important risk factor for cardiovascular and cerebrovascular diseases. At present, the control rate of hypertension treatment standard is less than 50%, and it is still not effectively managed to a large extent. Despite numerous clinical studies and trials over the past four decades, the progress of new antihypertensive drugs has not been satisfactory. This review discusses recent advances in pharmacological and non-pharmacological treatments for patients with hypertension, and may provide new options for clinical hypertension treatment in the future.
